Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00684593 | A Study to Assess the Clinical Effects of Navarixin in Participants With Psoriasis (MK-7123-009) | PHASE2 | COMPLETED | 31 | — | — | Jun 1, 2007 | Oct 1, 2007 | Feb 5, 2019 | - | — |
PASI score is a means to qualify the extent and severity of psoriatic lesions. The total score is calculated as the sum of the extent and severity of lesions on the head, arms, trunk, and legs and the score can range from 0 (no symptoms) to 72 (maximum symptoms).
| Arm | Type | Description |
|---|---|---|
| Navarixin | EXPERIMENTAL | Navarixin 30 mg administered orally once daily for 28 days. |
| Placebo | PLACEBO_COMPARATOR | Matching placebo to Navarixin administered orally once daily for 28 days. |
| Name | Type | Description |
|---|---|---|
| Navarixin 10 mg | DRUG | Navarixin capsules orally, once daily for 28 days. |
| Placebo | OTHER | Matching placebo capsules to Navarixin orally, once daily for 28 days. |
Inclusion Criteria: * Body Mass Index (BMI) 19 to 34, BMI = weight (kg)/height (m\^2). * Must have a diagnosis of psoriasis vulgaris (PASI \>8) present for at least 1 year. Participants with an on-therapy PASI \<=8 at Screening may be considered for inclusion. Participants must be discussed with th...